Acute pericarditis associated with COVID-19 infection
DOI:
https://doi.org/10.17533/udea.iatreia.130Keywords:
COVID-19, pericarditis, SARS-CoV-2Abstract
Infection by coronavirus type 2 that causes severe acute respiratory syndrome (SARS-CoV-2) has been associated with multiple cardiovascular manifestations. The mechanism by which the virus affects the heart is under discussion; however, it has been proposed that the angiotensinconverting enzyme 2 (ACE2) serves as a direct entry point for the virus; likewise, the state of inflammation mediated by cytokine storm can generate multiorgan failure, explaining some cardiac manifestations.
The main associations to the cardiovascular system reported in COVID-19 infection are acute coronary syndrome, acute heart failure, cardiogenic shock and arrhythmias. Acute pericarditis is an inflammatory syndrome of mainly viral etiology, and its relationship to SARS-CoV-2 infection seems infrequent, with few reports in the literature. We present the case of a patient who developed pericarditis, concomitant with SARS-CoV-2 infection.
Downloads
References
(1) Chakraborty C, Sharma AR, Sharma G, Bhattacharya M, Lee SS. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): Diagnostic and proposed therapeutic options. Eur Rev Med Pharmacol Sci. 2020;24(7)4016-26. DOI 10.26355/EURREV_202004_20871.
(2) Atri D, Siddiqi HK, Lang JP, Nauffal V, Morrow DA, Bohula EA. COVID-19 for the Cardiologist: Basic Virology, Epidemiology, Cardiac Manifestations, and Potential Therapeutic Strategies. JACC Basic Transl Sci. 2020 Apr 10;5(5):518-36. DOI 10.1016/j.jacbts.2020.04.002.
(3) Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020 Jul;38(7):1504-07. DOI 10.1016/j.ajem.2020.04.048.
(4) Wu L, O’Kane AM, Peng H, Bi Y, Motriuk-Smith D, Ren J. SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management. Biochem Pharmacol. 2020 Aug;178:114114. DOI 10.1016/j.bcp.2020.114114.
(5) Imazio M, Gaita F, LeWinter M. Evaluation and Treatment of Pericarditis: A Systematic Review. JAMA. 2015 Oct 13;314(14):1498-506. DOI 10.1001/jama.2015.12763.
(6) Tung-Chen Y. Acute pericarditis due to COVID-19 infection: An underdiagnosed disease? Med Clin (Barc). 2020 Jul 10;155(1):44-5. DOI 10.1016/j.medcli.2020.04.007.
(7) Naqvi SGZ, Naseeb U, Fatima K, Riffat S, Memon AG. Acute Pericarditis and Pericardial Effusion in a Hypertensive COVID-19 Patient. Cureus. 2020 Sep 29;12(9):e10705. DOI 10.7759/cureus.10705.
(8) Kumar R, Kumar J, Daly C, Edroos SA. Acute pericarditis as a primary presentation of COVID-19. BMJ Case Rep. 2020 Aug 18;13(8):e237617. DOI 10.1136/bcr-2020-237617.
(9) Tufo-Pereyra A, Scatularo CE, Cardone F, Grancelli H. [Pericarditis por SARS-CoV-2: informe de caso]. Arch Cardiol Mex. 2021 Jun 2. Spanish. DOI 10.24875/ACM.21000033.
(10) Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020 May-Jun;14(3):247-250. DOI 10.1016/j.dsx.2020.03.013.
(11) Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Jul 1;5(7):811-818. DOI 10.1001/jamacardio.2020.1017.
(12) Imazio M, Demichelis B, Parrini I, Giuggia M, Cecchi E, Gaschino G, et al. Day-hospital treatment of acute pericarditis: a management program for outpatient therapy. J Am Coll Cardiol. 2004 Mar 17;43(6):1042-6. DOI 10.1016/j.jacc.2003.09.055.
(13) Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015 Nov 7;36(42):2921-2964. DOI 10.1093/eurheartj/ehv318.
(14) Ariyarajah V, Spodick DH. Acute pericarditis: diagnostic cues and common electrocardiographic manifestations. Cardiol Rev. 2007 Jan-Feb;15(1):24-30. DOI 10.1097/01.crd.0000210645.89717.34.
(15) Chiabrando JG, Bonaventura A, Vecchié A, Wohlford GF, Mauro AG, Jordan JH, et al. Management of Acute and Recurrent Pericarditis: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Jan 7;75(1):76-92. DOI 10.1016/j.jacc.2019.11.021.
(16) Lund LC, Kristensen KB, Reilev M, Christensen S, Thomsen RW, et al. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study. PLoS Med. 2020 Sep 8;17(9):e1003308. DOI 10.1371/journal.pmed.1003308.
(17) Reyes AZ, Hu KA, Teperman J, Wampler Muskardin TL, Tardif JC, Shah B, Pillinger MH. Anti-inflammatory therapy for COVID-19 infection: the case for colchicine. Ann Rheum Dis. 2021 May;80(5):550-557.DOI 10.1136/annrheumdis-2020-219174.
(18) Tardif JC, Bouabdallaoui N, L’Allier PL, Gaudet D, Shah B, Pillinger MH. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebocontrolled, multicentre trial. Lancet Respir Med. 2021 May 27:S2213-2600(21)00222-8. DOI 10.1016/S2213-2600(21)00222-8.
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Universidad de Antioquia
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Papers published in the journal are available for use under the Creative Commons license, specifically Attribution-NonCommercial-ShareAlike 4.0 International.
The papers must be unpublished and sent exclusively to the Journal Iatreia; the author uploading the contribution is required to submit two fully completed formats: article submission and authorship responsibility.
